Belite Bio (BLTE) Cash from Operations (2024 - 2025)

Belite Bio (BLTE) posted quarterly Cash from Operations of 10385000.0 for Q4 2025, down 125.71% year-over-year from 40390012.68 in Q4 2024, and down 125.71% quarter-over-quarter from 4601000.0 in Q4 2024.

Belite Bio (BLTE) Cash from Operations (2024 - 2025) Analysis & Trends

Belite Bio's Cash from Operations history runs 2 years deep, the most recent figure standing at 10385000.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.13 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 813.00 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -387.32 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 462.82 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -1.76 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 728.46 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 326.72 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -88.83 Mn
10 Belite Bio 6.40 Bn 6.40 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -10.39 Mn
Dec 31, 2025 -10.39 Mn
Dec 31, 2024 -4.60 Mn
Dec 31, 2024 -4.60 Mn